We have signed an exclusive 12-month option agreement with Silk Road Therapeutics to acquire an orphan drug candidate for #Behçets Disease. The topical muco-adherent formulation of Pentoxifylline to treat oral ulcers has FDA Fast Track and Orphan Designation, positive Phase 2 data, and is positioned for potential 505(b)(2) regulatory pathway in the U.S. that can result in a much less expensive and much faster route to approval and commercialisation. There is a clear unmet medical need for an effective treatment for this rare disease, which currently has no cure. Behçet's Disease causes inflammation of blood vessels and tissues, resulting in debilitating symptoms, the most common being oral ulcers which impacts essential functions like eating, drinking and speaking. Read full announcement here: https://lnkd.in/ePAg63sW #POLB #Behçets #BehçetsDisease #raredisease #orphan
Poolbeg Pharma plc
Biotechnology Research
Committed to the development and commercialisation of innovative medicines. Ticker: POLB
About us
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
- Website
-
https://www.poolbegpharma.com/
External link for Poolbeg Pharma plc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Locations
-
Primary
Queen Mary BioEnterprises Innovation Centre, 42 New Road
London, E1 2AX, GB
-
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin 2, D02 T292, IE
Employees at Poolbeg Pharma plc
-
Eddie Gibson
Associate at Wickenstones Ltd
-
Jeremy Skillington, PhD
Chief Executive Officer at Poolbeg Pharma
-
Brendan Buckley
Chief Medical Officer at Teckro
-
Cathal Friel
Chairman and Co-Founder at Open Orphan Plc (now hVIVO plc) & Poolbeg Pharma Plc, Co-Founder & Director at European Green Transition, Co-Founder of…
Updates
-
We entered an exclusive option agreement to acquire an orphan drug candidate. Here is an overview of the Orphan Drug Candidate tPTX for Behçet's Disease from Timothy Cote, the CEO of Silk Road Therapeutics at our recent Investor Meet Company presentation. ☑️ Demonstrating superiority over standard of care 🎯 Addressing unmet need 🏃 Positioned for a potential 505(b)(2) approval pathway in the U.S Watch the full Investor Meet Company presentation: https://lnkd.in/edmN3aEp #POLB #POLBF #BehçetsDisease
-
Conference Reminder 🚨 we are attending the upcoming Biotechnology Innovation Organization International Convention on 3-6 June in San Diego, California. Meet with the team by connecting via the BIO One-on-One Partnering System: https://lnkd.in/eEDtKaAK #POLB #POLBF #BIOConvention #SanDiego #BIO24
-
Our CEO Jeremy Skillington, PhD featured on the latest Optimum Strategic Communications podcast episode dedicated to 🤖#ArtificialIntelligence in drug development, alongside the CEO & Co-founder of SimBioSys, Inc. 🔬AI in the drug development & pharma space 🦾AI overcoming industry challenges 🔍 Ethical considerations 🚀 Poolbeg Pharma plc's AI Programmes Make sure to tune in🎧 https://lnkd.in/dZWYypZM #AI #POLB #DrugDevelopment
-
We will be presenting with PI World at 2pm on Wednesday 20 June. Tune in 👂 to hear the latest updates from Poolbeg Pharma plc, register to attend💻 here: https://lnkd.in/gAEWQUzJ #POLBF #CompanyPresentation
-
Our CEO Jeremy Skillington, PhD caught up with Sarah Lowther to recap on our exciting recent news: ✅ Exclusive Option to Acquire Orphan Drug Candidate 🤝 Appointment of Joint Broker ☑️ Significant POLB 001 Patent Granted in the US Tune in: https://lnkd.in/etwznd7C #POLB #POLBF
Immense promise for cashed up Poolbeg Pharma
https://www.youtube.com/
-
Our CEO Jeremy Skillington, PhD was delighted to have connected with so many new & existing investors at yesterday's Mello Events in London. Thank you to everyone who joined our presentations & we look forward to connecting with you again soon 🚀 #POLB #POLBF #MelloEvent #London
-
Our latest deck is available to download ⬇️ on our website. Click on the link below to download our latest deck, watch our most recent presentations & see our upcoming events: https://lnkd.in/d4VZaMfT #POLB #CompanyPresentation
-
Our CEO Jeremy Skillington, PhD presents our latest Company presentation deck on DirectorsTalk Interviews. Tune in to learn more about how Poolbeg Pharma plc is positioned to generate value for shareholders, while addressing significant unmet medical needs across multiple disease areas. 🔬Revenue focussed business model 🎯High value programmes for partnering 🙌 Industry leading team 💪 Robust financial position Watch here: https://lnkd.in/eQBcj3yV #POLB #CompanyPresentation #DirectorsTalk
-
Shining a light on International Behçet’s Awareness Day. At our recent Investor Meet Company presentation, Timothy Cote provided an overview of the disease: 🔍Rare inflammatory immune disease with no cure 🩺 Lifelong symptoms 👩⚕️ Impact on patients Spread the word to help raise awareness on this debilitating disease. Learn more: https://lnkd.in/ejWgbBtd #BehçetsDisease #RaisingAwareness #InternationalBehçetsAwareness #POLB